Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
telbermin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| placebo | DRUG | Topically applied |
| telbermin | DRUG | Topically applied |
Inclusion Criteria: * Ability and willingness to comply with the following: study drug gel application and dressing changes as instructed; use offloading footwear and practice of rubbing prevention (shear injury) of the study ulcer for the duration of the study; adherence to study requirements or u...
Telbermin is being developed for the treatment of diabetic foot ulcers. It is a topical small molecule intended to induce healing of these wounds. Development is at Phase 2, and the clinical program has focused on patients with diabetic foot ulcers rather than healthy volunteers.
Telbermin targets FLT1 and KDR, which are vascular endothelial growth factor receptors. It acts as an agonist at these receptors. By engaging FLT1 and KDR, the drug is designed to promote vascular endothelial growth factor signaling relevant to wound healing in diabetic foot ulcers.
Telbermin is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the sponsor behind the clinical development program for this topical agent in diabetic foot ulcers.
Telbermin is in Phase 2 clinical development. It is an investigational agent and has not been approved for commercial use. The completed Phase 2 study evaluated topical recombinant human vascular endothelial growth factor for healing diabetic foot ulcers.
Telbermin has been studied in one clinical trial, NCT00351767, titled a study to assess the effect of topical recombinant human vascular endothelial growth factor for induction of healing of diabetic foot ulcers. That Phase 2 trial is completed and enrolled 170 participants. It was randomized, double blind, and placebo controlled.
Telbermin is a topical recombinant human vascular endothelial growth factor studied for diabetic foot ulcer healing. The Phase 2 trial NCT00351767 describes the agent in those terms, so references to topical recombinant human vascular endothelial growth factor in that study refer to telbermin.